Medical Cannabis Market Research Report - Global Forecast till 2027

Global Medical Cannabis Market Research Report: By Product form (Powders, Solids, Ointments and creams, Oil, Others), By Derivative (Cannabidiol, Tetrahydrocannabinol), By Application (Arthritis, Cancer, Alzheimer’s Disease, Others) and By Distribution Channel (Retail pharmacy, Online stores, Others) – Forecast to 2027

ID: MRFR/HC/6896-HCR | February, 2021 | Region : Global

Market Forecast


Global Medical Cannabis Market is expected to cross USD 52.35 Billion by 2025 at a CAGR of 15.4% during the forecast period.


The rising prevalence of chronic diseases and other medical conditions is set to drive the demand for medical cannabis.


Medical cannabis is most commonly prescribed for the treatment of arthritis, cancer, Alzheimer’s disease, schizophrenia, and others. Approximately 9.6 million people deaths due to cancer were reported in 2018, globally. Also, around 70% of these cancer-caused deaths occurred in low- and middle-income countries.


Market Synopsis


The increasing legalization of medical marijuana in various countries is expected to drive the growth of the global medical cannabis market.


In October 2016, Columbia legalized the use of cannabis as a medical treatment for various diseases and disorders. Moreover, it was also mentioned that in November 2016 in the US, voters in Florida, Arkansas, Montana, and North Dakota permitted initiatives to expand the medical use of cannabis.


Many companies are legalizing the use of cannabis for manufacturing drugs due to the increase in the application of cannabis in the medical field, which ultimately drives the growth of the market.


Market USP/Influencers


There has been a significant rise in the research & development initiatives of cannabinoid and related topics. In 2017, the National Institute of Health supported 330 projects and spent USD 140 million on the research & development of cannabinoid.


Market Drivers



  • High consumption of cannabis. About 147 million people, which approximately constitutes 2.5% of the world population, consume cannabis annually. In the present decade, the use of cannabis has increased more rapidly compared to other substances. There has been a rapid growth in cannabis consumption since the 1960s and is only rising in developed countries such as North America, Western Europe, and Australia.

  • Rising prevalence of chronic diseases and other medical conditions. Medical marijuana is safe and effective for improving symptoms such as sleep disorders, anxiety, and pain caused by chronic illnesses in adults.

  • The recent legalization of medical marijuana in various countries. Cannabis has been approved for medical use in 33 states of the US which include California, and Washington DC, as of November 2018.

  • Financial support by various private and government organizations for cannabinoid research

  • A rise in geriatric population


Market Restraints



  • Increasing the illegal use of marijuana. Approximately 28% of the global population misuse pharmaceutical drugs and one of the most commonly available is cannabis. Also, the most common illegal drugs used by people aged 14 and over were cocaine, cannabis, ecstasy, and amphetamine.

  • Stringent government policies


Segmentation


By Product form



  • Powders: Largest segment as it is one of the most conventional and affordable ways of use with effective The powder form can be dissolved in any liquid and consume as recommended.

  • Solids: Fastest segment and can be consumed in the form of capsules made from dried leaves of marijuana. The solid form is available as gum and resins.

  • Ointments and creams: Ointments are used as a pain reliever and reduce inflammation.

  • Oil: Oil products of marijuana contain two active chemical compounds—cannabidiol and tetrahydrocannabinol—with medical benefits.

  • Others: Others include lozenges, tinctures, smoking dried buds.


By Derivative



  • Cannabidiol (CBD): Component of marijuana. Largest segment as it is one of the most prevalent of the active ingredients of cannabis.

  • Tetrahydrocannabinol (THC): Psychoactive compound in marijuana. Available in the form of oils, tinctures, and capsules, among others.


By Application



  • Arthritis: Increase in research regarding the use of cannabis for medical purposes such as arthritis. An estimated two-third Canadians use cannabis for medical purposes to manage arthritis symptoms.

  • Cancer: Fastest growing segment in the medical cannabis market. The number of new cases of cancer is 439.2 per 100,000 men and women per year based on 2011–2015 cases in the US.

  • Alzheimer’s Disease: Largest segment. Alzheimer’s disease is the sixth-leading cause of death in the US and the fifth-leading cause of death among those aged 65 and older globally.

  • Schizophrenia: Endocannabinoid system is involved in neurotransmission and helps to regulate functions such as sleep, cognition, emotion. Thus, driving the growth of the market.

  • Others: This segment includes chronic pain and mental disorders.


By Distribution Channel



  • Retail pharmacy: The largest segment as many retail & pharmacy stores across the world provide cannabis products.

  • Online stores: The fastest segment due to relaxed regulations on the sale of cannabis in several countries. Additionally, the patient can upload their prescription and medicines through online stores.

  • Others: This segment includes hospital pharmacies, among others.


By Region



  • Americas: The largest regional market. Approximately 22.2 million Americans of 12 years of age and older use cannabis and related products for medical purposes.



  • Europe: The use of medical marijuana to treat chronic conditions is most prevalent in this region.



  • Asia-Pacific: The fastest-growing regional market for medical cannabis. The rising geriatric population and the increasing prevalence of cancer cases are expected to drive the growth of the market in this region.



  • Middle East & Africa: Increasing healthcare expenditure and rising government funding drive the demand for the medical cannabis market in this region.


Key Players



  • Canopy Growth Corporation (Canada)

  • Aphria, Inc. (Canada)

  • Aurora Cannabis (Canada)

  • Maricann Inc. (Canada)

  • Tilray (Canada)

  • GW Pharmaceuticals PLC (UK)

  • United Cannabis (US)

  • Medical Marijuana, Inc. (US)

  • Cannabis Sativa Inc. (US)

  • CanniMed Ltd (Canada)

  • MediPharm Labs (Canada)

  • GBSciences Inc. (US)

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. Regulatory Framework

6. GLOBAL MEDICAL CANNABIS MARKET, BY PRODUCT FORM

6.1. Overview

6.2. Powders

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Solids

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Ointments and Creams

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Oil

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVE

7.1. Overview

7.2. Cannabidiol (CBD)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Tetrahydrocannabinol (THC)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL MEDICAL CANNABIS MARKET, BY APPLICATION

8.1. Overview

8.2. Arthritis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Alzheimer’s Disease

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5. Schizophrenia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.6. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL

9.1. Overview

9.2. Retail Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3. Online Stores

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10. GLOBAL MEDICAL CANNABIS MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. Italy

10.3.1.4. Spain

10.3.1.5. UK

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPANY LANDSCAPE

11.1.1. Overview

11.1.2. Competitive Analysis

12. COMPANY PROFILES

12.1. Canopy Growth Corporation

12.1.1. Company Overview

12.1.2. Product form Overview

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Aphria, Inc.

12.2.1. Company Overview

12.2.2. Product form Overview

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Aurora Cannabis

12.3.1. Company Overview

12.3.2. Product form Overview

12.3.3. Financial Overview

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. MARICANN INC.

12.4.1. Company Overview

12.4.2. Product form Overview

12.4.3. Financial Overview

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Tilray

12.5.1. Company Overview

12.5.2. Product form Overview

12.5.3. Financial Overview

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. GW Pharmaceuticals PLC

12.6.1. Company Overview

12.6.2. Product form Overview

12.6.3. Financial Overview

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. United Cannabis

12.7.1. Company Overview

12.7.2. Product form Overview

12.7.3. Financial Overview

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Medical Marijuana, Inc.

12.8.1. Company Overview

12.8.2. Product form Overview

12.8.3. Financial Overview

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Cannabis Sativa Inc.

12.9.1. Company Overview

12.9.2. Product form Overview

12.9.3. Financial Overview

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Emerald Health Therapeutics Inc.

12.10.1. Company Overview

12.10.2. Product form Overview

12.10.3. Financial Overview

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. CanniMed Ltd

12.11.1. Company Overview

12.11.2. Product form Overview

12.11.3. Financial Overview

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. MediPharm Labs

12.12.1. Company Overview

12.12.2. Product form Overview

12.12.3. Financial Overview

12.12.4. Key Developments

12.12.5. SWOT Analysis

12.12.6. Key Strategies

12.13. GBSciences Inc.

12.13.1. Company Overview

12.13.2. Product form Overview

12.13.3. Financial Overview

12.13.4. Key Developments

12.13.5. SWOT Analysis

12.13.6. Key Strategies

12.14. Others

13. APPENDIX

13.1. References

13.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL MEDICAL CANNABIS MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL MEDICAL CANNABIS MARKET ESTIMATES & FORECAST, 2020-2027(USD MILLION)

TABLE 3 GLOBAL MEDICAL CANNABIS MARKET, BY PRODUCT FORM, 2020-2027(USD MILLION)

TABLE 4 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2027(USD MILLION)

TABLE 5 GLOBAL MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2027(USD MILLION)

TABLE 6 GLOBAL MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 7 GLOBAL MEDICAL CANNABIS MARKET, BY REGION, 2020-2027(USD MILLION)

TABLE 8 NORTH AMERICA: MEDICAL CANNABIS MARKET, BY PRODUCT FORM, 2020-2027(USD MILLION)

TABLE 9 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2027(USD MILLION)

TABLE 10 NORTH AMERICA: MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2027(USD MILLION)

TABLE 11 NORTH AMERICA: MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 12 US: MEDICAL CANNABIS MARKET, BY PRODUCT FORM, 2020-2027(USD MILLION)

TABLE 13 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2027(USD MILLION)

TABLE 14 US: MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2027(USD MILLION)

TABLE 15 US: MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 16 CANADA: MEDICAL CANNABIS MARKET, BY PRODUCT FORM, 2020-2027(USD MILLION)

TABLE 17 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2027(USD MILLION)

TABLE 18 CANADA: MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2027(USD MILLION)

TABLE 19 CANADA: MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 20 LATIN AMERICA: MEDICAL CANNABIS MARKET, BY PRODUCT FORM, 2020-2027(USD MILLION)

TABLE 21 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2027(USD MILLION)

TABLE 22 LATIN AMERICA: MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2027(USD MILLION)

TABLE 23 LATIN AMERICA: MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 24 EUROPE: MEDICAL CANNABIS MARKET, BY PRODUCT FORM, 2020-2027(USD MILLION)

TABLE 25 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2027(USD MILLION)

TABLE 26 EUROPE: MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2027(USD MILLION)

TABLE 27 EUROPE: MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 28 WESTERN EUROPE: MEDICAL CANNABIS MARKET, BY PRODUCT FORM, 2020-2027(USD MILLION)

TABLE 29 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2027(USD MILLION)

TABLE 30 WESTERN EUROPE: MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2027(USD MILLION)

TABLE 31 WESTERN EUROPE: MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 32 EASTERN EUROPE: MEDICAL CANNABIS MARKET, BY PRODUCT FORM, 2020-2027(USD MILLION)

TABLE 33 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2027(USD MILLION)

TABLE 34 EASTERN EUROPE: MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2027(USD MILLION)

TABLE 35 EASTERN EUROPE: MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 36 ASIA-PACIFIC: MEDICAL CANNABIS MARKET, BY PRODUCT FORM, 2020-2027(USD MILLION)

TABLE 37 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2027(USD MILLION)

TABLE 38 ASIA-PACIFIC: MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2027(USD MILLION)

TABLE 39 ASIA-PACIFIC: MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA: MEDICAL CANNABIS MARKET, BY PRODUCT FORM, 2020-2027(USD MILLION)

TABLE 41 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVES, 2020-2027(USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA: MEDICAL CANNABIS MARKET, BY APPLICATION, 2020-2027(USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA: MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2027(USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL MEDICAL CANNABIS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL MEDICAL CANNABIS MARKET

FIGURE 4 GLOBAL MEDICAL CANNABIS MARKET SHARE, BY PRODUCT FORM, 2020 (%)

FIGURE 5 GLOBAL MEDICAL CANNABIS MARKET SHARE, BY DERIVATIVES, 2020 (%)

FIGURE 6 GLOBAL MEDICAL CANNABIS MARKET SHARE, BY APPLICATION, 2020 (%)

FIGURE 7 GLOBAL MEDICAL CANNABIS MARKET SHARE, BY DISTRIBUTION CHANNEL, 2020 (%)

FIGURE 8 GLOBAL MEDICAL CANNABIS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 AMERICAS: MEDICAL CANNABIS MARKET SHARE BY REGION, 2020 (%)

FIGURE 10 NORTH AMERICA: MEDICAL CANNABIS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 EUROPE: MEDICAL CANNABIS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 12 WESTERN EUROPE: MEDICAL CANNABIS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 ASIA-PACIFIC: MEDICAL CANNABIS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 14 MIDDLE EAST & AFRICA: MEDICAL CANNABIS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 15 GLOBAL MEDICAL CANNABIS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 16 CANOPY GROWTH CORPORATION: SEGMENTAL REVENUE

FIGURE 17 CANOPY GROWTH CORPORATION: REGIONAL REVENUE

FIGURE 18 APHRIA, INC.: KEY FINANCIALS

FIGURE 19 APHRIA, INC.: SEGMENTAL REVENUE

FIGURE 20 APHRIA, INC.: REGIONAL REVENUE

FIGURE 21 AURORA CANNABIS: KEY FINANCIALS

FIGURE 22 AURORA CANNABIS: SEGMENTAL REVENUE

FIGURE 23 AURORA CANNABIS: REGIONAL REVENUE

FIGURE 24 MARICANN INC.: KEY FINANCIALS

FIGURE 25 MARICANN INC.: SEGMENTAL REVENUE

FIGURE 26 MARICANN INC.: REGIONAL REVENUE

FIGURE 27 TILRAY: KEY FINANCIALS

FIGURE 28 TILRAY: SEGMENTAL REVENUE

FIGURE 29 TILRAY: REGIONAL REVENUE

FIGURE 30 GW PHARMACEUTICALS PLC.: KEY FINANCIALS

FIGURE 31 GW PHARMACEUTICALS PLC.: SEGMENTAL REVENUE

FIGURE 32 GW PHARMACEUTICALS PLC.: REGIONAL REVENUE

FIGURE 33 UNITED CANNABIS: KEY FINANCIALS

FIGURE 34 UNITED CANNABIS: SEGMENTAL REVENUE

FIGURE 35 UNITED CANNABIS: REGIONAL REVENUE

FIGURE 36 MEDICAL MARIJUANA, INC.: KEY FINANCIALS

FIGURE 37 MEDICAL MARIJUANA, INC.: SEGMENTAL REVENUE

FIGURE 38 MEDICAL MARIJUANA, INC.: REGIONAL REVENUE

FIGURE 39 CANNABIS SATIVA INC.: KEY FINANCIALS

FIGURE 40 CANNABIS SATIVA INC.: SEGMENTAL REVENUE

FIGURE 41 CANNABIS SATIVA INC.: REGIONAL REVENUE

FIGURE 42 EMERALD HEALTH THERAPEUTICS INC.: KEY FINANCIALS

FIGURE 43 EMERALD HEALTH THERAPEUTICS INC.: SEGMENTAL REVENUE

FIGURE 44 EMERALD HEALTH THERAPEUTICS INC.: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Medical Cannabis Market